Skip to main content

Table 1 Patients’ characteristics and oncological data

From: ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study

Variables

ALPPS vs. TSH/PVE analysis

ALPPS (n = 21)

TSH/PVE (n = 37)

p value

Demographics

 Sex, m/f (%)

8 (38)/13 (62)

25 (68)/12 (32)

.029

 Age (years)

60 (52–71)

60 (52–67)

.686

 BMI (kg/m2)

24 (20–30)

25 (23–29)

.340

 ASA, n (%)

  

.460

  I

2 (10)

1 (3)

 

  II

5 (24)

12 (42)

 

  III

14 (67)

24 (65)

 

 Rescue ALPPS after failed TSH, n (%)

6 (29)

n.a.

n.a.

Oncologic characteristics

 Timing: synchronous/metachronous

9 (43)/12 (57)

24 (65)/13 (35)

.104

 Site of primary

  

.145

  Right-sided colon

6 (29)

4 (11)

 

  Left-sided colon

10 (48)

17 (46)

 

  Rectum

5 (24)

16 (43)

 

 T category primary

  

.581

  I/II

3 (14)

3 (9)

 

  III/IV

18 (86)

29 (91)

 

 N category primary

  

.001

  N0

9 (43)

2 (6)

 

  N1

12 (57)

30 (94)

 

 Preoperative chemotherapy (y/n)

20 (95)/1 (5)

21 (57)/16 (43)

 

 Number of chemotherapy lines, n (%)

  

.038

  First-line treatment

20 (95)

27 (73)

 

  Second-line treatment

3 (14)

7 (19)

 

 Number of cycles of chemotherapy

8 (6–13)

6 (0–13)

.243

 Chemotherapeutic substance in first line, n (%)

  

.312

  Oxaliplatin

13 (62)

14 (38)

 

  Irinotecan

4 (19)

2 (5)

 

  Oxaliplatin and Irinotecan

2 (10)

6 (16)

 

  Other/unknown

2 (10)

5 (14)

 

 Chemotherapeutic substance in second line, n (%)

  

.788

  Oxaliplatin

0

1 (14)

 

  Irinotecan

1 (33)

3 (43)

 

  Oxaliplatin and Irinotecan

2 (67)

2 (29)

 

  Other

0

1 (14)

 

 Antibody utilization, n (%)

14 (67)

17 (46)

.128

 Antibody, n (%)

  

.476

  Bevacizumab

7 (50)

12 (71)

 

  Cetuximab

5 (36)

4 (24)

 

  Panitumumab

2 (14)

1 (6)

 

 Response to chemotherapy, n (%)#

  

.794

  Stable disease

9 (45)

13 (38.2)

 

  Partial remission

10 (50)

20 (58.8)

 

  Progressive disease

1 (5)

1 (2.9)

 

 Number of lesions at hepatectomy*

3 (1–9)

3 (1–8)

.686

 Largest tumor diameter at hepatectomy (mm)*

42 (10–130)

33 (4–107)

.237

Liver function and clinical chemistry

 Albumin (g/l)

41 (34–44)

41 (39–46)

.279

 AST (U/l)

32 (27–57)

31 (24–41)

.189

 ALT (U/l)

32 (22–47)

27 (20–38)

.197

 GGT (U/l)

109 (47–316)

67 (34–173)

.080

 Total bilirubin (mg/dl)

0.4 (0.2–0.6)

0.4 (0.3–0.6)

.336

 Platelet count (/nl)

254 (196–295)

257 (199–295)

.986

 Alkaline Phosphatase (U/l)

148 (91–189)

92 (76–131)

.029

 Prothrombin time (%)

100 (84–104)

100 (93–111)

.200

 Hemoglobin (g/dl)

11.9 (9.9–13.1)

13.2 (12.4–14.5)

.003

  1. ALPPS associating liver partition and portal vein ligation for staged hepatectomy, ALT alanine aminotransferase, AP alkaline phosphatase, ASA American Society of Anesthesiologists classification, AST aspartate aminotransferase, BMI body mass index, CRP c-reactive protein, GGT gamma glutamyltransferase, INR international normalized ratio
  2. #For TSH/PVE patients who did not undergo preoperative chemotherapy, inter-stage chemotherapy was evaluated to determine response to systemic therapy. Data presented as median and interquartile range if not noted otherwise
  3. *Median and range. Categorical data were compared using the chi-squared test, fisher’s exact test or linear-by-linear association according to scale and number of cases. Data derived from continuous variables of different groups were compared by Mann-Whitney U Test
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us